«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

29卷

期数:

2023年04期

页码:

354-359

栏目:

生物信息学专题

出版日期:

2023-07-10

文章信息/Info

Title:

Association of ITSN1 gene with chemosensitivity and prognosis in ovarian cancer

文章编号:

1006-8147（2023）04-0354-06

作者:

张宁; 金嘉琪; 张少璐; 马勇杰

天津医科大学肿瘤医院肿瘤细胞生物学实验室，国家恶性肿瘤临床医学研究中心，天津市恶性肿瘤临床医学研究中心，乳腺癌防治教育部重点实验室，天津市“肿瘤防治”重点实验室，天津300060

Author(s):

ZHANG Ning¹; 2; JIN Jia-qi¹; 2; ZHANG Shao-lu¹; 2; MA Yong-jie¹; 2

1.Cancer Cell Biology Laboratory，Tianjin Medical University Cancer Institute&Hospital，National Clinical Research Center for Cancer；Tianjin′s Clinical Research Center for Cancel，Key Laboratory of Breast Cancer Prevention and Therapy，Tianjin Medical University， Ministry of Education；Key Laboratory of Cancer Prevention and Therapy，Tianjin;2. Tianjin 300060，China

关键词:

ITSN1; 上皮性卵巢癌; 化疗敏感性; 基因表达

Keywords:

ITSN1; Epithelial ovarian cancer; sensitivity to chemotherapy; gene expression

分类号:

R737.31

DOI:

-

文献标志码:

A

摘要:

目的：探究交叉蛋白1（ITSN1）基因在卵巢癌化疗敏感性中的作用和临床意义。方法：利用GEO、Kaplan-Meier数据库分析ITSN1在卵巢癌化疗敏感组和耐药组中的表达差异以及与化疗患者预后的关系。在此基础上，进一步分析ITSN1表达水平与信号通路的关系，构建ITSN1蛋白相互作用网络。结果：在GSE51373（t=3.691，P=0.001）和GSE148003（t=16.67，P=0.0000）数据集中化疗敏感组的ITSN1表达水平显著高于耐药组。生存分析结果显示，ITSN1高表达的卵巢癌铂类化疗患者的总生存期（OS，HR=0.85，95%CI：0.72～0.99，P=0.04）和无进展生存期（PFS，HR=0.85，95%CI：0.74～0.99，P=0.031）显著提高。在多西他赛化疗的卵巢癌患者中，ITSN1高表达患者的生存率明显改善。在不同组织学类型和组织病理学级别的铂类基础化疗卵巢癌患者中，ITSN1mRNA高表达患者的预后更好。进一步分析ITSN1表达水平与信号通路的关系发现，ITSN1可能参与DNA修复通路，并且与DNA修复呈负相关（均P<0.05）。ITSN1的相互作用蛋白包括RAD18等。结论：ITSN1在卵巢癌铂类化疗敏感组中显著高表达且与铂类基础化疗患者预后呈显著正相关，并可能通过与RAD18相互作用参与调控DNA修复通路，进而提高铂类化疗敏感性。

Abstract:

Objective：To investigate the role and clinical significance of cross protein 1（ ITSN1） gene in the chemosensitivity of ovarian cancer. Methods：GEO and Kaplan-Meier databases were used to analyze the difference of ITSN1 expression between the chemosensitive group and the chemoresistant group of ovarian cancer，and the relationship between ITSN1 expression and the prognosis of patients with chemotherapy. On this basis，the relationship between ITSN1 expression level and signaling pathways was further analyzed，and the protein interaction network of ITSN1 was constructed. Results：In GSE51373（ t=3.691，P=0.001） and GSE148003（ t=16.67，P=0.000 0） datasets， the expression level of ITSN1 in the chemosensitive group was significantly higher than that in the chemoresistant group. Survival analysis showed that the overall survival（ OS，HR=0.85，95%CI：0.72-0.99，P=0.04） and progression-free survival（ PFS，HR=0.85，95%CI：0.74-0.99，P=0.031）of ovarian cancer patients with high ITSN1 expression were significantly improved after platinum-based chemotherapy. In ovarian cancer patients treated with docetaxel chemotherapy，the survival rate of patients with high ITSN1 expression was significantly improved. Among ovarian cancer patients with different histological types and histopathological grades treated with platinum-based chemotherapy，patients with high ITSN1 mRNA expression have better prognosis. Further analysis of the relationship between the expression level of ITSN1 and signal pathways showed that ITSN1 may be involved in the DNA repair pathway and was negatively correlated with DNA repair（ all P<0.05）. In addition，the ITSN1 protein interaction network was constructed and the correlation expression analysis showed that ITSN1 interacting proteins included RAD18 and others. Conclusion：ITSN1 is highly expressed in platinum-based chemotherapy sensitive ovarian cancer and is positively correlated with the prognosis of patients receiving platinum-based chemotherapy. ITSN1 may participate in the regulation of DNA repair pathway by interacting with RAD18 to improve the sensitivity of platinum-based chemotherapy.

参考文献/References:

[1] KURNIT K C，FLEMING G F，LENGYEL E. Updates and new op－tions in advanced epithelial ovarian cancer treatment[J]. Obstet Gy－necol，2021，137（ 1）：108-121.
[2] KUROKI L，GUNTUPALLI S R. Treatment of epithelial ovarian can－cer[J]. Bmj，2020，371：m3773.
[3] TSIBULAK I，ZEIMET A G，MARTH C. Hopes and failures in front-line ovarian cancer therapy[J]. Crit Rev Oncol Hematol，2019，143：14-19.
[4] BUECHEL M，HERZOG T J，WESTIN S N，et al. Treatment of pa－tients with recurrent epithelial ovarian cancer for whom platinum is still an option[J]. Ann Oncol，2019，30（ 5）：721-732.
[5] LU S，LI Y，ZHU C，et al. Managing cancer drug resistance from the perspective of inflammation[J]. J Oncol，2022，2022：3426407.
[6] TSYBA L，NIKOLAIENKO O，DERGAI O，et al. Intersectin mul－tidomain adaptor proteins：regulation of functional diversity[J]. Gene， 2011，473（ 2）：67-75.
[7] ZHANG H，GUO Z，LIU X，et al. Endocytic protein intersectin1-S shuttles into nucleus to suppress the DNA replication in breast can－cer[J]. Cell Death Dis，2021，12（ 10）：922.
[8] SHAO Y，CHONG W，LIU X，et al. Alternative splicing-derived in－tersectin1-L and intersectin1-S exert opposite function in glioma progression[J]. Cell Death Dis，2019，10（ 6）：431.
[9] XIE C，XIONG W，LI J，et al. Intersectin 1（ ITSN1）identified by comprehensive bioinformatic analysis and experimental validation as a key candidate biological target in breast cancer[J].Onco Targets Ther，2019，12：7079-7093.
[10] SONG M，CUI M，LIU K. Therapeutic strategies to overcome cis－platin resistance in ovarian cancer[J]. Eur J Med Chem，2022，232：114205.
[11] FANG F，CARDENAS H，HUANG H，et al. Genomic and epigenom－ic signatures in ovarian cancer associated with resensitization to platinum drugs[J]. Cancer Res，2018，78（ 3）：631-644.
[12] POVEDA A，VERGOTE I，TJULANDIN S，et al.Trabectedin plus pe－gylated liposomal doxorubicin in relapsed ovarian cancer：outcomes in the partially platinum-sensitive （ platinum-free interval 6-12 months）subpopulation of OVA-301 phaseⅢrandomized trial[J]. Ann Oncol，2011，22（ 1）：39-48.
[13] MOORE K N，SECORD A A，GELLER M A，et al.Niraparib monother－apy for late-line treatment of ovarian cancer（QUADRA）：a multicen－tre，open-label，single-arm，phase 2 trial[J]. Lancet Oncol，2019， 20（ 5）：636-648.
[14] KAMPAN N C，MADONDO M T，MCNALLY O M，et al. Paclitaxel and its evolving role in the management of ovarian cancer[J]. Biomed Res Int，2015，2015：413076.
[15] LIHUA P，CHEN X Y，WU T X.Topotecan for ovarian cancer [J]. Cochrane Database Syst Rev，2008，2008（ 2）：Cd005589.
[16] KAKU T，OGAWA S，KAWANO Y，et al. Histological classification of ovarian cancer[J]. Med Electron Microsc，2003，36（ 1）：9-17.
[17] WU Q，YANG Z，NIE Y，et al. Multi-drug resistance in cancer chemotherapeutics：mechanisms and lab approaches[J]. Cancer Lett， 2014，347（ 2）：159-166.
[18] WANG J，SEEBACHER N，SHI H，et al. Novel strategies to prevent the development of multidrug resistance（ MDR） in cancer[J]. Onco－target，2017，8（ 48）：84559-84571.
[19] LI Y J，LEI Y H，YAO N，et al. Autophagy and multidrug resistance in cancer[J]. Chin J Cancer，2017，36（ 1）：52.
[20] FERREIRA S，DUTREIX M. DNA repair inhibitors to enhance ra－diotherapy：progresses and limitations[J]. Cancer Radiother，2019， 23（ 8）：883-890.
[21] MAKOVEC T. Cisplatin and beyond：molecular mechanisms of ac－tion and drug resistance development in cancer chemotherapy [J]. Radiol Oncol，2019，53（ 2）：148-158.
[22] GHOSH S. Cisplatin：the first metal based anticancer drug[J]. Bioorg Chem，2019，88：102925.
[23] NAMBIAR T S，BILLON P，DIEDENHOFEN G，et al. Stimulation of CRISPR-mediated homology-directed repair by an engineered RAD18 variant[J]. Nat Commun，2019，10（ 1）：e3395.
[24] LI X，ZOU S，ZHOU L，et al. RAD18 confers radioresistance of esophagus squamous cell carcinoma through regulating p-DNA-PKcs[J]. Cancer Med，2022，11（ 20）：3809-3819.
[25] YU R，HU Y，ZHANG S，et al. LncRNA CTBP1-DT-encoded mi－croprotein DDUP sustains DNA damage response signalling to trigger dual DNA repair mechanisms[J]. Nucleic Acids Res，2022，50（14）：8060-8079.

相似文献/References:

[1]黄小娟,王俊艳,齐文慧,等.Axl及其配体Gas6在I型和 II型上皮性卵巢癌中的表达和意义[J].天津医科大学学报,2014,20(05):342.
　HUANG Xiao-juan,WANG Jun-yan,QI Wen-hui,et al.Expression of Axl and its ligand in type I and II epithelial ovarian carcinoma and its clinical significance[J].Journal of Tianjin Medical University,2014,20(04):342.
[2]张莹华,马勇杰.ITSN1 mRNA预测乳腺癌预后的价值[J].天津医科大学学报,2019,25(05):440.
　ZHANG Ying-hua,MA Yong-jie.The value of ITSN1 mRNA in predicting the prognosis of breast cancer[J].Journal of Tianjin Medical University,2019,25(04):440.
[3]张莹华 综述,马勇杰 审校.ITSN1蛋白磷酸化的研究进展[J].天津医科大学学报,2019,25(06):666.
[4]王军,张占薪,王佳佳,等.LncRNA FAM83H-AS1和miR-136在上皮性卵巢癌中的表达及临床意义[J].天津医科大学学报,2024,30(06):485.[doi:10.20135/j.issn.1006-8147.2024.06.0485]
　WANG Jun,ZHANG Zhanxin,WANG Jiajia,et al.Expression and clinical significance of LncRNA FAM83H-AS1 and miR-136 in epithelial ovarian cancer[J].Journal of Tianjin Medical University,2024,30(04):485.[doi:10.20135/j.issn.1006-8147.2024.06.0485]

备注/Memo

备注/Memo:

基金项目:天津市教委科研计划项目（2022KJ215）；天津市医学重点学科（专科）建设项目（TJYXZDXK-009A）
作者简介:张宁（1997-），女，博士在读，研究方向：肿瘤学；
通信作者：马勇杰，E-mail：mayongjie@tjmuch.com。

常用功能

更新日期/Last Update: 2023-07-10